Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AtriCure, Inc. is a medical device company focused on the treatment of atrial fibrillation and the management of left atrial appendage complications. The company operates within the cardiac surgery and electrophysiology segments of the broader medical technology industry. Its core offerings include surgical ablation systems, minimally invasive devices, and appendage management products used primarily in hospital settings by cardiothoracic surgeons and electrophysiologists.
The company’s primary revenue drivers are its Ablation Products and Left Atrial Appendage Management (LAAM) Products, which are designed to address unmet clinical needs in the treatment of cardiac arrhythmias and stroke prevention. AtriCure is positioned as a specialized provider with a strong focus on surgical solutions, differentiating itself from competitors that emphasize catheter-based approaches. Founded in 2000, the company has evolved from a single-product developer into a diversified cardiac surgery platform through product innovation, regulatory approvals, and targeted acquisitions.
Business Operations
AtriCure operates through two primary business segments: Ablation Products and Left Atrial Appendage Management Products. The ablation segment includes devices and generators used during open-heart and minimally invasive procedures to create precise lesions that disrupt abnormal electrical pathways. The LAAM segment includes mechanical occlusion devices designed to reduce stroke risk by excluding the left atrial appendage from circulation.
The company generates revenue through direct sales to hospitals and healthcare systems, primarily in the United States, with expanding international sales through a combination of direct commercial teams and distributors. AtriCure controls proprietary ablation technologies, including bipolar radiofrequency and cryothermal energy platforms, and maintains manufacturing and R&D capabilities internally. Its operating structure includes wholly owned subsidiaries supporting international sales and regulatory activities.
Strategic Position & Investments
AtriCure’s strategy centers on expanding adoption of surgical and hybrid atrial fibrillation treatments, increasing penetration of left atrial appendage management devices, and broadening its minimally invasive portfolio. Growth initiatives include clinical evidence generation, physician education, and investments in next-generation technologies designed to simplify procedures and improve outcomes.
The company has completed targeted acquisitions to strengthen its technology base and procedural reach, including the acquisition of nContact Surgical, which expanded its minimally invasive ablation offerings. AtriCure continues to invest in emerging hybrid treatment approaches that combine surgical and catheter-based techniques, positioning the company at the intersection of cardiac surgery and electrophysiology.
Geographic Footprint
AtriCure is headquartered in North America, with its principal executive offices in Ohio, United States. The majority of its revenue is generated in the U.S., reflecting strong adoption within domestic cardiac surgery programs and established reimbursement pathways.
Internationally, the company maintains a growing presence across Europe, Asia-Pacific, and select markets in Latin America through subsidiaries and distributor partnerships. These regions represent strategic growth opportunities, supported by regulatory approvals, expanded clinical data, and increasing prevalence of atrial fibrillation globally.
Leadership & Governance
AtriCure is led by an executive team with experience in medical devices, cardiac surgery, and regulated healthcare markets. The leadership emphasizes disciplined growth, clinical evidence development, and long-term value creation through innovation and operational execution.
- Michael H. Carrel – President and Chief Executive Officer
- Todd J. Usen – Chief Financial Officer
- Timothy J. O’Donnell – Chief Operating Officer
- Jeffrey E. Ebert – Chief Technology Officer
- Andrew M. Park – Chief Commercial Officer
The company operates under a governance framework aligned with U.S. public company standards, with oversight provided by an independent board of directors and a strategic focus on compliance, product quality, and shareholder accountability.